Profound Medical Corp.

NASDAQ:PROF

Medical - Devices

Healthcare
$6.91 +4.11%

+$0.27 today

Market cap
$253.09M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $3.76High $8.95

Volume 0.08M

Average 0.12M

PROF EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Profound Medical Corp.NASDAQ: PROF

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$7.81M, compared with -$10.97M a year earlier. Trailing-twelve-month EBITDA was -$37.85M.

Context

  • EBITDA amounted to 252.8% of revenue in FY2025, up 1.1 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of -$26.4M (+36.2%) for the fiscal year ending Dec 2026, a step up from the -61.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.81M-6.0% QoQ
Last fiscal yearDec 2025
-$41.41M-61.8% YoY
LTMMar 2026
-$37.85M+9.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.8%+37.2%+8.4 pp
1 year-61.8%+36.2%+98.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(41.41M) USD
Year-over-year change
-61.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PROF compares with its peers on the latest reported figures

  • PROF's LTM Mar 2026 EBITDA of -$37.85M is the 5th highest of the 11 companies compared; the peer median is -$46.13M.
  • Its year-over-year change of +9.1% is the 4th highest of 11, against a peer median of -2.7%.
  • EBITDA amounts to 200.6% of revenue for PROF, versus a peer median of 83.1%.
PROF Competitors Peer median
EBITDA for PROF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LNSRLENSAR, Inc.LTM Mar 2026$33.96M +165.0%—58.8%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026-$20.95M +5.5%—46.7%
STIMNeuronetics, Inc.LTM Mar 2026-$25.7M +34.0%—17.0%
MXCTMaxCyte, Inc.LTM Mar 2026-$34.64M +5.7%—107.3%
PROFProfound Medical Corp.LTM Mar 2026-$37.85M +9.1%—200.6%
OWLTOwlet, Inc.LTM Mar 2026-$43.26M -365.8%—40.4%
NNOXNano-X Imaging Ltd.LTM Dec 2025-$49M -11.0%—376.3%
PREPrenetics Global LimitedLTM Mar 2026-$51.68M +9.1%—45.4%
AVRAnteris Technologies Global Corp.LTM Mar 2026-$92.94M -14.3%—5021.0%
CATXPerspective Therapeutics, Inc.LTM Mar 2026-$110.64M -31.7%—17902.8%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026-$262.46M -2046.7%—8872.8%
Peer median (excluding PROF) -$46.13M-2.7%—83.1%

Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.87M6.68M7.2M10.17M16.38M
Cost of Revenue3.92M3.66M2.82M3.47M4.79M
Gross Profit2.95M3.02M4.38M6.7M11.59M
Gross Margin43.0%45.2%60.9%65.9%70.8%
Research & Development15.28M14.69M14.38M16.15M20.96M
Selling, General & Admin17.97M17.93M18.62M22.02M32.61M
Operating Expenses33.24M35.15M33M38.17M53.57M
Depreciation & Amortization1.88M1.6M1.15M891.06K569.8K
EBITDA(28.65M)(26.6M)(26.78M)(25.59M)(41.41M)
EBITDA Margin-416.8%-398.2%-372.0%-251.7%-252.8%
Operating Income(30.29M)(32.13M)(28.62M)(31.47M)(41.98M)
Operating Margin-440.7%-480.9%-397.5%-309.6%-256.3%
Interest Income203.2K1.05M1.64M1.37M1.09M
Interest Expense66.41K167.11K770K00
Other Income / Expenses(303K)3.74M(81K)4.99M(1.08M)
Income Before Tax(30.59M)(28.38M)(28.7M)(26.48M)(43.06M)
Pre-Tax Margin-445.1%-424.8%-398.6%-260.5%-262.9%
Income Tax Expense105K287K(128K)(1.9K)256.41K
Net Income(30.7M)(28.67M)(28.57M)(26.48M)(43.32M)
Net Margin-446.7%-429.1%-396.8%-260.4%-264.4%
EPS (Basic)(1.50)(1.38)(1.35)(1.07)(1.43)
EPS (Diluted)(1.50)(1.38)(1.35)(1.07)(1.43)
Weighted Avg Shares20.46M20.83M21.18M24.77M30.23M
Weighted Avg Shares (Diluted)20.47M20.83M21.18M24.77M30.23M

Profound Medical Corp.

NASDAQ:PROF

Intrinsic Alpha fair value

Locked

Current Price

$6.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.